In the current study, we investigated the expression of two other important immunomodulatory molecules, the transmembrane receptor Fas (CD95/APO-1) and its ligand, FasL (CD95L), in the PB of patients with metastatic BC. This evidence concerns the gene FAS and breast cancer.